Translating knowledge

IOCBTech is a technology transfer office and subsidiary company of IOCB (the Institute of Organic Chemistry and Biochemistry CAS). The company matches results of basic research done at the IOCB with needs of commercial partners to ultimately bring new ideas in medicinal chemistry, material sciences, and other fields of chemistry to human use.

Oxytocin

OXYTOCINTM

1958
Remestyp

TERLIPRESINTM

1965
Dermazulen

DERMAZULENTM

1969
Minirin

DESMOPRESINTM

1970
Usal

USALTM

1975
Adiuretin

ADIURETINTM

1975
Duvira gel

DUVIRA GELTM

1980
Duratocin

DURATOCINTM

1985
Vistide

VISTIDETM

1996

VIREADTM

2001

HEPSERATM

2002

TRUVADATM

2004

ATRIPLATM

2006

COMPLERATM

2011

STRIBILDTM

2012

Projects & Opportunities

Here you can explore our projects which are available for co-development or licensings.

About IOCB Tech

The IOCB Tech team supports management and decision-making processes in Target Research Groups of IOCB e.g. by due diligence analyses, market potential studies, and project feasibility evaluation. Moreover, the company is responsible for networking and industry partner search or negotiations of contracts and agreements in the field of intellectual property.

An integral part of IOCB Tech’s duties is the organization and development of spin-off companies on IOCB’s technology platform.

IOCB Team

News

05/16
2019

SHINE and IOCB Prague Enter Lu-177 Process License Agreement

05/16/2019
Novel Separation Method Accelerates SHINE’s Path to Market for Cancer Treatment Isotopes May 15th, 2019Prague, Czechia – SHINE Medical Technologies, Inc. (SHINE), a Wisconsin company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, and the Institute of Organic Chemistry and Biochemistry of the…

Where to meet us?

Bio Europe Spring 2019

When: 24/03/2019 – 27/03/2019
Where: Vienna, Austria (map)

Description:

You can follow IOCBTech via Twitter with the Hashtag #IOCBTech…